Want to join the conversation?
Medical solutions provider $BSX announced 3Q15 sales of $1.888Bil compared to its guidance of $1.790-1.840Bil, representing an increase of 2% in operational revenue growth on a reported basis. This performance was driven by strong sales and differentiated adjusted operating margin expansion. $BSX also reported a GAAP loss of $0.15 per share.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.